Interní Med. 2005; 7(9): 395-398

Hypertriglyceridemia (pathogenesis, diagnosis, therapy)

MUDr. Jan Buryška
OKB Městská nemocnice, Ostrava

While in previous years, priority in the field of lipidology was devoted to total cholesterol(TCH), and LDL cholesterol (LDLch), nowadays this priority shifts towards populations with moderately increased concentration of LDLch and with dyslipidemia typical for 2nd-type diabetes mellitus (DM2T) and towards metabolic syndrome (MS). Dyslipidemias are characterized by mildly increased concentration of triglycerides (Tg), decreased concentration of HDL cholesterol (HDLch) and by the boost of small-density LDL particles. Besides these highly aterogenic dyslipidemias, there exist hypertriglyceridemias (HTG) with a low risk of cardiovascular disease (CVD). Pronounced HTG caused by for instance chylomicronemic syndrome are not aterogenic, but these conditions may be life threatening to patients with acute pancreatitis.

Keywords: Key words: hypertriglyceridemia, chylomicronemia, aterogenic dyslipidemia, pancreatitis, fibrates, niacin

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Buryška J. Hypertriglyceridemia (pathogenesis, diagnosis, therapy). Interní Med. 2005;7(9):395-398.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Assman G, Schulte H. Prospective Cardiovascular Munster Study. Am. J. Cardiol 1992, 70: 733-737. Go to original source... Go to PubMed...
    2. Cucuzzela M, Smith PC, Nashelsky J. When should we treat isolated high triglycerides? Journal of Family Practice, Feb. 2004.
    3. Cífková R, et al. Prevence kardiovaskulárních onemocnění v dospělém věku (Společná doporučení českých odborných společností 2005): v tisku.
    4. Češka R. Epidemiologie a současné trendy farmakoterapie dyslipidemií v České republice a metabolický syndrom jako globální hrozba současnosti. Česko-francouzská diskusní fóra, Praha, 24. 5. a 4. 10. 2004. Farmakoekonomika léčby dyslipidemií a MS, 2004; 4: 1-2.
    5. Darwin D. Metabolic Syndrome: Time for Action. Am Fam Physician 2004; 69: 2875-2882. Go to PubMed...
    6. Dhiraj Yadav and C.S. Pitchumoni. Issue in Hyperlipidemic Pancreatitis. J. Clin. Gastroenterol. 2003; 36 (1): 54-62. Go to original source... Go to PubMed...
    7. Fung Michelle A, Frohlich JJ. Common problems in the management of hypetriglyceridemia. CMAJ, Nov. 26, 2002; 167 (11): 1261-1266.
    8. Ginsberg HN. Treatment for Patients with the Metabolic Syndrome. Am. J. Cardiol 2003; 91 (suppl): 29E-39E. Go to original source... Go to PubMed...
    9. Hyánek a spol. Dědičné metabolické poruchy. Avicenum 1991.
    10. Lemieux I, et al. Hypertriglyceridemic waist. Circulation 2000; 102: 179-184. Go to original source... Go to PubMed...
    11. Lewis A, Lookinland S, Beckstransd RL, Tiedeman ME. Treatment of hypertriglyceridemia with omega -3-fatty acids:a systematic rewiew. J. Am. Acad. Nurse Pract., 2004; Sep., 16 (9): 384-395. Go to original source... Go to PubMed...
    12. Mike Mitka. (Guidelines: New Lows for LDL Target Levels) JAMA, 2004; 292: 911-913.
    13. Mubaslat AA, Reaven P. The Metabolic Syndrome: Pathogenesis, Consequences and Treatment Strategies. Resident & Staff Physician. Jan 2005, vol. 51, No. 1: 1-8.
    14. Niaspan. Product Monograph. Merck, April 2004.
    15. Ravi GR, Pradeepa R, Mohan V. Hypertriglyceridemia and Coronary Artery Disease-An Update. Indian Heart J. 2004; 56: 21-26.
    16. Robins SJ. Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy? Curr Opin Lipiodol 2003; 14: 575-583. Go to original source... Go to PubMed...
    17. Soška Vladimír. Poruchy metabolizmu lipidů. Diagnostika a léčba. Grada Publishing, 2001.
    18. Souhrn pro praktické uplatnění Třetí zprávy skupiny odborníků Národního vzdělávacího cholesterolového programu (NCEP) pro vyhledávání, vyšetřování a léčbu hypercholesterolemie u dospělých (Panel pro léčbu dospělých III). JAMA - CS, září 2001; 9: 682-695.
    19. Vaverková H. Dyslipoproteinemie a diabetes mellitus. VL, 46, 2000; 9: 532-538.
    20. Wagh A, Stone NJ. Secondary causes of hypertriglyceridemia and pancreatitis. Clinica Chimica Acta, 2003; 21: 332. Go to original source...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.